000304594 001__ 304594
000304594 005__ 20251007135431.0
000304594 0247_ $$2doi$$a10.1038/s41590-025-02268-7
000304594 0247_ $$2pmid$$apmid:40954250
000304594 0247_ $$2ISSN$$a1529-2908
000304594 0247_ $$2ISSN$$a1529-2916
000304594 0247_ $$2altmetric$$aaltmetric:181418885
000304594 037__ $$aDKFZ-2025-01917
000304594 041__ $$aEnglish
000304594 082__ $$a610
000304594 1001_ $$00000-0001-5866-0501$$aAndrade, Augusto Faria$$b0
000304594 245__ $$aA spatial map of MAPK-activated immunosuppressive myeloid populations in pediatric low-grade glioma.
000304594 260__ $$aLondon$$bSpringer Nature Limited$$c2025
000304594 3367_ $$2DRIVER$$aarticle
000304594 3367_ $$2DataCite$$aOutput Types/Journal article
000304594 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1759838035_6323
000304594 3367_ $$2BibTeX$$aARTICLE
000304594 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000304594 3367_ $$00$$2EndNote$$aJournal Article
000304594 500__ $$a#EA:B310#LA:B310# / 2025 Oct;26(10):1794-1806
000304594 520__ $$aPediatric low-grade gliomas (pLGGs) are mitogen-activated protein kinase (MAPK) pathway-activated brain tumors prevalent in children and are associated with morbidity despite favorable survival. Here using imaging mass cytometry, we spatially characterized at the single-cell level the tumor microenvironment (TME) of 120 pLGG cases, considering age, molecular drivers, brain location and tumor subtype. Our analysis identified myeloid cells-including resident microglia and bone marrow-derived macrophages-as the predominant immune population in the TME, particularly in optic pathway tumors. Additionally, we discovered an immune signature predictive of progression-free survival. Spatial analysis identified specific cellular interactions, notably myeloid-myeloid contacts and macrophage-enriched regions harboring MAPK-activated, TIM-3+ myeloid cells, suggesting an immunosuppressive TME. Our study provides a comprehensive resource on the immune landscape of these pLGGs and underscores the immunosuppressive role of diverse myeloid infiltrates. These findings also indicate that combining TIM-3 blockade with MAPK inhibition might be a promising therapeutic strategy to target both the TME and oncogenic MAPK activation in pLGG tumors.
000304594 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000304594 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000304594 7001_ $$0P:(DE-He78)a5e60710c7515b3e1de74ced6928a9dd$$aSigaud, Romain$$b1$$eFirst author$$udkfz
000304594 7001_ $$00000-0001-8449-9221$$aPuligandla, Evan$$b2
000304594 7001_ $$aLiu, Bridget$$b3
000304594 7001_ $$aKarimi, Elham$$b4
000304594 7001_ $$00000-0002-3258-4296$$aAnnett, Alva$$b5
000304594 7001_ $$aRezanejad, Morteza$$b6
000304594 7001_ $$00000-0002-2724-6401$$aJawhar, Wajih$$b7
000304594 7001_ $$aTaylor, Robert$$b8
000304594 7001_ $$00009-0000-7350-5681$$aCao, Yi$$b9
000304594 7001_ $$0P:(DE-He78)6e4a8cc4eb35e694f95453ed8a927a83$$aSchmid, Simone$$b10
000304594 7001_ $$0P:(DE-He78)a23e88cc676489fe05be8c178ceaf58e$$aSelt, Florian$$b11$$udkfz
000304594 7001_ $$aHernáiz Driever, Pablo$$b12
000304594 7001_ $$aHorn, Svea$$b13
000304594 7001_ $$0P:(DE-He78)8aad075b17d93a5636a34942bdbd7ee6$$aSievers, Philipp$$b14$$udkfz
000304594 7001_ $$00000-0002-0349-1955$$aPrinz, Marco$$b15
000304594 7001_ $$00000-0002-7720-8817$$aGlatzel, Markus$$b16
000304594 7001_ $$aMawrin, Christian$$b17
000304594 7001_ $$aHartmann, Christian$$b18
000304594 7001_ $$aMonoranu, Camelia-Maria$$b19
000304594 7001_ $$00000-0003-4804-5497$$aKonnikova, Liza$$b20
000304594 7001_ $$0P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88$$aSahm, Felix$$b21$$udkfz
000304594 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan$$b22$$udkfz
000304594 7001_ $$0P:(DE-He78)143af26de9d57bf624771616318aaf7c$$aWitt, Olaf$$b23$$udkfz
000304594 7001_ $$0P:(DE-He78)551bb92841f634070997aa168d818492$$aJones, David$$b24$$udkfz
000304594 7001_ $$aKoch, Arend$$b25
000304594 7001_ $$aKleinman, Claudia L$$b26
000304594 7001_ $$0P:(DE-He78)51bf9ae9cb5771b30c483e5597ef606c$$aCapper, David$$b27$$udkfz
000304594 7001_ $$00000-0001-8771-2577$$aWalsh, Logan$$b28
000304594 7001_ $$00000-0003-2485-3692$$aJabado, Nada$$b29
000304594 7001_ $$0P:(DE-He78)0be2f86573954f87e97f8a4dbb05cb0f$$aMilde, Till$$b30$$eLast author$$udkfz
000304594 773__ $$0PERI:(DE-600)2026412-4$$a10.1038/s41590-025-02268-7$$n10$$p1794-1806$$tNature immunology$$v26$$x1529-2908$$y2025
000304594 909CO $$ooai:inrepo02.dkfz.de:304594$$pVDB
000304594 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a5e60710c7515b3e1de74ced6928a9dd$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000304594 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6e4a8cc4eb35e694f95453ed8a927a83$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000304594 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a23e88cc676489fe05be8c178ceaf58e$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000304594 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8aad075b17d93a5636a34942bdbd7ee6$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000304594 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88$$aDeutsches Krebsforschungszentrum$$b21$$kDKFZ
000304594 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b22$$kDKFZ
000304594 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)143af26de9d57bf624771616318aaf7c$$aDeutsches Krebsforschungszentrum$$b23$$kDKFZ
000304594 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)551bb92841f634070997aa168d818492$$aDeutsches Krebsforschungszentrum$$b24$$kDKFZ
000304594 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)51bf9ae9cb5771b30c483e5597ef606c$$aDeutsches Krebsforschungszentrum$$b27$$kDKFZ
000304594 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0be2f86573954f87e97f8a4dbb05cb0f$$aDeutsches Krebsforschungszentrum$$b30$$kDKFZ
000304594 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000304594 9141_ $$y2025
000304594 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-13$$wger
000304594 915__ $$0StatID:(DE-HGF)3003$$2StatID$$aDEAL Nature$$d2024-12-13$$wger
000304594 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNAT IMMUNOL : 2022$$d2024-12-13
000304594 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-13
000304594 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-13
000304594 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-13
000304594 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-13
000304594 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-13
000304594 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-13
000304594 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-13
000304594 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-13
000304594 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-13
000304594 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-13
000304594 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-13
000304594 915__ $$0StatID:(DE-HGF)9930$$2StatID$$aIF >= 30$$bNAT IMMUNOL : 2022$$d2024-12-13
000304594 9202_ $$0I:(DE-He78)B310-20160331$$kB310$$lKKE Pädiatrische Onkologie$$x0
000304594 9201_ $$0I:(DE-He78)B310-20160331$$kB310$$lKKE Pädiatrische Onkologie$$x0
000304594 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000304594 9201_ $$0I:(DE-He78)BE01-20160331$$kBE01$$lDKTK Koordinierungsstelle Berlin$$x2
000304594 9201_ $$0I:(DE-He78)B300-20160331$$kB300$$lKKE Neuropathologie$$x3
000304594 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x4
000304594 9201_ $$0I:(DE-He78)B360-20160331$$kB360$$lPädiatrische Gliomforschung$$x5
000304594 9200_ $$0I:(DE-He78)B310-20160331$$kB310$$lKKE Pädiatrische Onkologie$$x0
000304594 980__ $$ajournal
000304594 980__ $$aVDB
000304594 980__ $$aI:(DE-He78)B310-20160331
000304594 980__ $$aI:(DE-He78)HD01-20160331
000304594 980__ $$aI:(DE-He78)BE01-20160331
000304594 980__ $$aI:(DE-He78)B300-20160331
000304594 980__ $$aI:(DE-He78)B062-20160331
000304594 980__ $$aI:(DE-He78)B360-20160331
000304594 980__ $$aUNRESTRICTED